Last reviewed · How we verify
immediate Cervarix, delayed MenVeo vaccine
This is a vaccination regimen combining two separate vaccines: Cervarix (HPV vaccine) given immediately and Menhibrix or Menveo (meningococcal vaccine) given on a delayed schedule to provide protection against human papillomavirus and meningococcal disease.
This is a vaccination regimen combining two separate vaccines: Cervarix (HPV vaccine) given immediately and Menhibrix or Menveo (meningococcal vaccine) given on a delayed schedule to provide protection against human papillomavirus and meningococcal disease. Used for Prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18, Prevention of meningococcal disease caused by serogroups A, C, W, and Y.
At a glance
| Generic name | immediate Cervarix, delayed MenVeo vaccine |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | vaccine combination |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | FDA-approved |
Mechanism of action
Cervarix is a bivalent HPV vaccine that stimulates immune response against HPV types 16 and 18, which cause cervical cancer. Menveo is a meningococcal conjugate vaccine that provides protection against serogroups A, C, W, and Y by inducing antibody responses against meningococcal polysaccharide capsules. The delayed administration schedule allows for sequential immune priming against both pathogens.
Approved indications
- Prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18
- Prevention of meningococcal disease caused by serogroups A, C, W, and Y
Common side effects
- Injection site pain/erythema
- Headache
- Myalgia
- Fatigue
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: